EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A SUBPOPULATION ANALYSIS OF UNITI/IM-UNITI LONG-TERM EXTENSION THROUGH 5 YEARS

Toshifumi Hibi  ¹     Byong Duk Ye  ²     Christopher Gasink  ³     Yuya Imai  ⁴     Carine Saadoun  ⁵     Jianmin Zhuo  ⁶     Shiho Kawamura  ^5    
1 Kitasato University, Tokyo, Japan
² Asan Medical Center, Seoul, Korea (Republic of)
³ Janssen Scientific Affairs, LLC, Horsham, United States
⁴ Janssen Pharmaceutical K.K., Tokyo, Japan
⁵ Janssen Pharmaceuticals Asia Pacific, Singapore, Singapore
⁶ Janssen China Research & Development, Shanghai

Session
IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)